ESTRO 2022 - Abstract Book

S1196

Abstract book

ESTRO 2022

Overall, the mean±SD age and pre-treatment PSA was 66.7±8.6 years and 53.3±75.9 ng/ml, respectively. 10 (23.3%) and 33 (76.7%) patients had M1 and N1 only disease, respectively. Table 1 depicts a comparison of clinicodemographics between the three groups; patients with M1 disease were significantly older compared to patients with N1 disease. The mean±SD duration of androgen deprivation therapy (ADT) use was 2.13±0.62 years and all patients had completed ADT by time of analysis. At a mean±SD time to follow-up of 4.67±3.02 years, 2/10 (20%) patients with M1 disease and 5/33 (15.2%) patients with N1 only disease experienced biochemical failure. bPFS were not significantly different between the two groups (Mantel-Cox p=0.552, Figure 1). Kaplan-Meier estimate (SE) for survival time was 10.6 (0.810) years. Conclusion Radiation therapy for the treatment of oligometastatic prostate cancer yielded bPFS rates of 80% and 84.8% for patients with M1 and N1 only disease.

Table 1. Clinicodemographics of all patients undergoing radiation therapy for M1 and N1 only disease.

Figure 1. Kaplan-Meier of bPFS for patients with M1 and N1M0 disease.

PO-1411 Number of PSMA-PET positive lymph nodes affects outcome in node positive prostate cancer patients

S. Spohn 1,2,3 , V. Birkenmaier 1 , J. Ruf 4 , T. Sprave 1,2 , A. Grosu 1,2 , C. Zamboglou 1,2,3,5

1 University Medical Center Freiburg, Department of Radiation Oncology, Freiburg, Germany; 2 German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany; 3 Faculty of Medicine - University of Freiburg, Berta-Ottenstein- Programme, Freiburg, Germany; 4 University Medical Center Freiburg, Department of Nuclear Medicine, Freiburg, Germany; 5 European University of Cyprus, German Oncology Center, Limassol, Cyprus Purpose or Objective National comprehensive cancer network recommends external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) for newly diagnosed node positive (cN1) prostate cancer (PCa) patents as the preferred treatment